Nurix Therapeutics Reports Successful Outcomes from NX-5948 Trial in Relapsed Refractory CLL Patients at EHA2024 Congress.

Electra Therapeutics Reveals New Clinical Findings at EHA2024 from Active Phase 1b Trial of ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH).

Cabaletta Bio Releases Favorable Early Clinical Results from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Studies of CABA-201.

Kymera Therapeutics Unveils Fresh Clinical Data from Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Event.

Galapagos unveils promising new results for CD19 CAR-T therapy GLPG5101 in non-Hodgkin lymphoma at EHA 2024.

FDA authorizes Blincyto® (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during consolidation stage.

Aimovig™ (erenumab) is an injectable human monoclonal antibody (mAb) co-developed and co-marketed by Novartis and Amgen, indicated for the preventive treatment of migraines in adults.

Celltrion presents encouraging phase III data for CT-P47, a biosimilar of RoActemra® (tocilizumab), in RA patients at EULAR 2024.

The researchers conducted a prospective docking of extensive compound libraries against the unoptimized AlphaFold2 (AF2) models of the σ2 receptor and the 5-HT2A receptor.

ELREXFIO™ Demonstrates Over Two-Year Median Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma.

Jun 18th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Vertex Showcases Promising Long-Term Results for CASGEVY™ (exagamglogene autotemcel) at the 2024 EHA Congress.